Evaluation of hexane extract of Chlorophytum alismifolium on hyperglycaemia and neuropathic pain in high-fat diet and streptozotocin-induced diabetic Wistar rats

Document Type: Original article

Authors

1 Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical sciences, Ahmadu Bello University, Zaria

2 Department of Pharmacology and Therapeutics, Ahmadu Bello University, Zaria-Nigeria

3 Department of Human Physiology, College of Medicine, Ahmadu Bello University, Zaria-Nigeria

4 Pharmacology and Therapeutics, Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Nigeria

5 Department of Pharmacognosy and Drug Development, Ahmadu Bello University, Zaria-Nigeria.

6 Department of Pharmacology and Therapeutics, Bayero University, Kano, Nigeria.

Abstract

Background & Aim:Diabetes mellitus is an intricate metabolic disorder of the endocrine system associated with complications that result in morbidity and mortality. This study was carried out to establish the antihyperglycaemic profile and the effect of hexane extract of Chlorophytum alismifolium (HECA) on diabetic neuropathy in high-fat diet and streptozotocin-induced hyperglycaemic Wistar rats.
Experimental: C. alismifolium tubers were extracted with n-hexane using a soxhlet apparatus. The LD50 was determined using the OECD 425 guideline. The animals were served high fat diet for 6 weeks and then administered 40 mg/kg of streptozotocin to induce diabetes. Experimental groups were set up using normal rats in group I and hyperglycaemic rats in 5 groups of 5 rats each. Group I and II were the normal and hyperglycaemic controls given distilled water (1 mL/kg); groups III, IV and V were given categorized doses of HECA (150, 300 and 600 mg/kg) respectively. Group VI received pioglitazone (20 mg/kg). Fasting glycaemic level was evaluated and diabetic neuropathy was investigated using thermal and mechanical methods.
Results: Phytochemical screening showed the presence of flavonoids, alkaloids, steroids and triterpenes while the oral median toxic dose was estimated to be >5000 mg/kg. Administration of HECA at all doses evidently (p < 0.05) reduced the glycaemic level relative to the hyperglycaemic group and over time. Treatment with HECA also remarkably (p < 0.05) lowered the withdrawal times in both thermal and mechanical hyperalgesic methods of diabetic neuropathy compared to the hyperglycaemic control.
Recommended applications/industries: The findings revealed that the hexane extract of Chlorophytum alismifolium has beneficial effects and can be applied in the management of diabetes and some of its complications.

Keywords


Article Title [Persian]

ارزیابی عصاره هگزان Chlorophytum alismifolium بر هیپرگلیسمی و درد نوروپاتیک موشهای صحرایی دیابتی ناشی از رژیم غذایی پرچرب و استرپتوزوتوسین

Authors [Persian]

  • عبدالحکیم ابوبکر 1
  • ادریس محمد ماج 2
  • یوسف تانکو 3
  • جوسف آنوکا 4
  • عزالدین عبدالرحمن 5
  • عبدالهی نظیفی 6
1 گروه داروسازی و درمان ، دانشکده علوم دارویی ، دانشگاه احمدو بلو ، زاریا
2 گروه داروسازی و درمان ، دانشکده علوم دارویی ، دانشگاه احمدو بلو ، زاریا
3 گروه فیزیولوژی انسانی ، کالج پزشکی ، دانشگاه احمدو بلو ، زاریا-نیجریه
4 گروه داروسازی و درمان ، دانشکده علوم دارویی ، دانشگاه احمدو بلو ، زاریا
5 گروه فارماکوگنوزی و توسعه دارو ، دانشگاه احمدو بلو ، زاریا-نیجریه
6 گروه دارویی و درمانی ، دانشگاه بایرو ، کانو ، نیجریه
Abstract [Persian]

Background & Aim:Diabetes mellitus is an intricate metabolic disorder of the endocrine system associated with complications that result in morbidity and mortality. This study was carried out to establish the antihyperglycaemic profile and the effect of hexane extract of Chlorophytum alismifolium (HECA) on diabetic neuropathy in high-fat diet and streptozotocin-induced hyperglycaemic Wistar rats.
Experimental: C. alismifolium tubers were extracted with n-hexane using a soxhlet apparatus. The LD50 was determined using the OECD 425 guideline. The animals were served high fat diet for 6 weeks and then administered 40 mg/kg of streptozotocin to induce diabetes. Experimental groups were set up using normal rats in group I and hyperglycaemic rats in 5 groups of 5 rats each. Group I and II were the normal and hyperglycaemic controls given distilled water (1 mL/kg); groups III, IV and V were given categorized doses of HECA (150, 300 and 600 mg/kg) respectively. Group VI received pioglitazone (20 mg/kg). Fasting glycaemic level was evaluated and diabetic neuropathy was investigated using thermal and mechanical methods.
Results: Phytochemical screening showed the presence of flavonoids, alkaloids, steroids and triterpenes while the oral median toxic dose was estimated to be >5000 mg/kg. Administration of HECA at all doses evidently (p < 0.05) reduced the glycaemic level relative to the hyperglycaemic group and over time. Treatment with HECA also remarkably (p < 0.05) lowered the withdrawal times in both thermal and mechanical hyperalgesic methods of diabetic neuropathy compared to the hyperglycaemic control.
Recommended applications/industries: The findings revealed that the hexane extract of Chlorophytum alismifolium has beneficial effects and can be applied in the management of diabetes and some of its complications.

Keywords [Persian]

  • Chlorophytum alismifolium
  • HECA
  • Hyperglycaemia
  • Neuropathy
  • Streptozotocin
Abubakar, A.,Danjuma, N.M., Chindo, B.A. and Nazifi, A.B. 2018. Anti-hyperglycaemic activity of tuber extract of Chlorophytum alismifolium Baker in streptozotocin-induced hyperglycaemic rats. Bulletin of Faculty of Pharmacy, Cairo University, 56 (1): 60–67.

Abubakar, A., Nauzo, A.H., Nazifi, A.B., Muhammad, Z., Maje, I.M. and Danjuma, N.M. 2019b. Analgesic and anti-inflammatory effects of Chlorophytum alismifolium extract in murine models. Journal of Herbal Drugs, 10 (3): 81–88.

Abubakar, A.,Nazifi, A.B., Ismail, H.F., Duke, K.A. and Edoh, T.D. 2019a. Safety assessment of Chlorophytum alismifolium tuber extract (Liliaceae): Acute and sub-acute toxicity studies in Wistar rats. Journal of Acute Disease, 8(1): 21–27.

Abubakar, A., Nazifi, A.B., Odoma, S., Shehu, S. And Danjuma, N.M. 2020. Anti-nociceptive activity of methanol extract of Chlorophytum alismifolium tubers in murine model of pain: Possible involvement of α-2 adrenergic receptor and KATP channels. Journal of Traditional and Complementary Medicine, 10(1): 1–6.

Alicic, R.Z., Rooney, M.T. and Tuttle, K.R. 2017. Diabetic kidney disease: challenges, progress, and possibilities. Clinical Journal of the American Society of Nephrology, 12(12): 2032–2045.

Al-Ishaq, R.K., Abotaleb, M., Kubatka, P., Kajo, K. and Büsselberg D. 2019. Flavonoids and their antidiabetic effects: cellular mechanisms and effects to improve blood sugar levels. Biomolecules, 9(9): 430.

American Diabetes Association (ADA). 2010. Diagnosis and classification of diabetes mellitus. Diabetes Care, 33: S62–S69.

Anjaneyulu, M. and Chopra, K. 2004. Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice. European Journal of Pharmacology, 497 (3): 285–292.

Basu, P. and Basu. A. 2020. In vitro and in vivo effects of flavonoids on peripheral neuropathic pain. Molecules, 25(5): 1171.

Bramlage, P., Gitt, A.K., Schneider, S., Deeg, E. and Tschope, D. and DiaRegis Study Group. 2014. Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up. Biomed Central Cardiovascular Disorders, 14: 162.

Brownrigg, J.R.W., Hughes, C.O., Burleigh, D., Karthikesalingam, A., Patterson, B.O., Holt, P.J., Thompson, M.M., de Lusignan, S., Ray, K.K. and Hinchliffe, R.J. 2016. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. The Lancet Diabetes and Endocrinology, 4(7): 588–597.

Burkill, H.M. 1995. The useful plant of West Tropical Africa. Royal Botanical Gardens, United Kingdom.

Callaghan, B.C., Little, A.A., Feldman, E.L. and Hughes, R.A. 2012. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database System Review, 6(6): CD007543.

Clerici, F., Gelmi, M.L. andPellegrino, S. 2008. In: Comprehensive Heterocyclic Chemistry III, Elsevier, Oxford, United Kingdom.

Colerangle, J.B., 2017. Preclinical development of nononcogenic drugs (small and large molecules). In: Faqi, A.S., (Ed.). A comprehensive guide to toxicology in nonclinical drug development. Academic Press, U.S. pp. 659–683.

Cordero, A., Lopez-Palop, R., Carrillo, P., Moreno-Arribas, J., Bertomeu-Gonzalez, V., Frutos, A., Garcia-Carrilero, M., Gunturiz, C. and Bertomeu-Martinez, V. 2016. Comparison of long-term mortality for cardiac diseases in patients with versus without diabetes mellitus. The American Journal of Cardiology, 117(7): 1088–1094.

Dutra, R.C., Simão da Silva, K.A., Bento, A.F., Marcon, R., Paszcuk, A.F., Meotti, F.C., Pianowski, L.F. and Calixto, J.B. 2012. Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: the involvement of cannabinoid system. Neuropharmacology, 63(4): 593–605.

Erhirhie, E.O., Ihekwereme, C.P. and Ilodigwe, E.E. 2018. Advances in acute toxicity testing: strengths, weaknesses and regulatory acceptance. Interdisciplinary Toxicology, 11(1): 5–12.

Evans, W.C. 2009. Trease and Evans Pharmacognosy, (16th Ed.) Elsevier Health Sciences, London, United Kingdom.

Forouzanfar. F. and Hosseinzadeh, H. 2018. Medicinal herbs in the treatment of neuropathic pain: a review. Iranian Journal of Basic Medical Sciences, 21(4): 347–358.

Hong, J.R., Choi, Y.J., Keum, G., Nam, G. 2017. Synthesis and diabetic neuropathic pain-alleviating effects of 2N-(pyrazol-3-yl) methylbenzo [d] isothiazole-1,1-dioxide derivatives. Bioorganic and Medicinal Chemistry, 25(17): 4677–4685.

International Diabetes Federation (IDF). 2019. IDF Diabetes Atlas (9th Ed.). 1–176.

Kontopantelis, E., Springate, D.A., Reeves, D., Ashcroft, D.M., Rutter, M.K., Buchan, I. and Doran, T. 2015. Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia, 58 (3): 505–518.

Kosacka, J., Nowicki, M., Kloting, M., Kern, N., Stumvoll, M., Bechmann, I., Serke, H. and Bluher, M. 2012. COMP-angiopoietin-1 recovers molecular biomarkers of neuropathy and improves vascularization in sciatic nerve of ob/ob mice. PLoS ONE, 7:e32881.

Laha, S. and Paul, S. 2019. Gymnema sylvestre (Gurmar): A potent herb with anti-diabetic and antioxidant potential. Pharmacognosy Journal, 11(2): 201–206.

Lennertz, R.C., Medler, K.A., Bain, J.L., Wright, D.E. and Stucky, C.L. 2011. Impaired sensory nerve function and axon morphology in mice with diabetic neuropathy. Journal of Neurophysiology, 106(2): 905–914.

Leoni, A., Locatelli, A., Morigi, R. and Rambaldi, M. 2014. Novel thiazole derivatives: a patent review (2008 - 2012. Part 2). Expert Opinion and Therapeutic Patents, 24(7): 759–777.

Ling, Q., Liu, M., Wu, M.X., Xu, Y., Yang, J., Huang, H.H. and Yu, C.X. 2014. Anti-allodynic and neuroprotective effects of Koumine, a Benth alkaloid, in a rat model of diabetic neuropathy. Biological and Pharmaceutical Bulletin. 37(5): 858–864.

Ma, B., Zhu, Z., Zhang, J., Ren, C. and Zhang, Q. 2020. Aucubin alleviates diabetic nephropathy by inhibiting NF-κB activation and inducing SIRT1/SIRT3-FOXO3a signaling pathway in high-fat diet/streptozotocin-induced diabetic mice. Journal of Functional Foods, 64: 103702.

Mohammedi, K., Woodward, M., Marre. M., Colagiuri, S., Cooper, M., Harrap, S., Mancia, G, Poulter, N., Williams, B., Zoungas, S. and Chalmers, J. 2017. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovacular Diabetology, 16(1): 95.

Müller, C.E. and Jacobson, K.A. 2011. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochimica et Biophysica Acta, 1808(5): 1290–1308.

Okoduwa, S.I.R., Umar, I.A., James, D.B. and Inuwa, H.M. 2017. Validation of the antidiabetic effects of Vernonia amygdalina Delile leaf fractions in fortified diet-fed streptozotocin-treated rat model of type-2 diabetes. Journal of Diabetology, 8(3): 74–85.

Organization for Economic Cooperation and Development. (OECD). 2001. Acute oral toxicity: Up and down procedure. OECD guidelines for the testing of chemicals, 425: 1–26.

Parveen, K., Khan, M.R., Mujeeb, M. and Siddiqui, WA. 2010. Protective effects of Pycnogenol on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats. Chemico-Biological Interactions, 186(2): 219–227.

Patil, V.S. and Khatib, N.A. 2020. Triterpene saponins from Barringtoniaacutangula (L.) Gaertn as a potent inhibitor of 11β-HSD1 for type 2 diabetes mellitus, obesity, and metabolic syndrome. Clinical Phytoscience, 6 (61):doi.org/10.1186/s40816-020-00210-y

Peng, Y., Gaoa, Y., Zhang, X., Zhang, C., Wang, X., Zhang, H., Wang, Z., Liu, Y. and Zhang, H. 2019. Antidiabetic and hepatoprotective activity of the roots of Calanthe fimbriata Franch. Biomedicine and Pharmacotherapy, 111: 60–7.

Randall, L.O. and Sellito, J.J. 1957. A method for measurement of analgesic activity on inflamed tissue. Archives Internationals de Pharmacodynamieet de Therapie, 111(4): 409–419.

Redfern, J., Kinninmonth, M., Burdass, D. and Verran, J. 2014. Using soxhlet ethanol extraction to produce and test plant material (essential oils) for their antimicrobial properties. Journal of Microbiology and Biology Education, 15(1): 45–46.

Schmiedebergs, N. 2017. Analgesic, antiallodynic and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl) propamide and 2-(2,5- dioxopyrrolidin-1-yl) butanamide in animal models of pain and epilepsy. Archives of Pharmacology, 390(6): 567–579.

Shinkai, H., Onogi, S., Tanaka, M., Shibata, T., Iwao, M., Wakitani, K. and Uchida, I. 1998. Isoxazolidine-3,5-dione and Noncyclic1,3-Dicarbonyl Compounds as Hypoglycemic Agents. Journal of Medicinal Chemistry, 41(11): 1927–1933.

Szkudelski, T. 2001.The mechanism of Alloxan and Streptozotocin action in beta cells of the rat’s pancreas. Physiological Research, 50 (6): 537-546.

Taylor, S.I., Accili, D. and Imai, Y. 1994. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes, 43(6): 735–740.

Vincent, A.M. and Feldman, E.L., 2004. New insights into the mechanisms of diabetic neuropathy. Reviews in Endocrine and Metabolic Disorders, 5(3): 227–236.

Vincent, A.M., Callaghan, B.C., Smith, A.L. and Feldman, E.L. 2011. Diabetic neuropathy: Cellular mechanisms as therapeutic targets. Nature Reviews Neurology, 7(10): 573–583.

Yang, X., Fang, P., Xiang, D. and Yang, Y. 2019. Topical treatments for diabetic neuropathic pain (Review). Experimental and Therapeutic Medicine, 17(3): 1963–1976.